EMVision Advances Regional Stroke Diagnosis Study with $337K Government Funding

• Site visits completed in remote South Australian hospitals
• CRC-P progress payment of $337,425 received
• Study integrates emu™ with telestroke services
• Focus on rural hospitals lacking timely CT access
• Findings expected to inform US Critical Access Hospital market

Regional Stroke Diagnosis Study Gains Momentum

EMVision Medical Devices Ltd (ASX:EMV) is advancing its government-backed Regional Benefits Study, designed to demonstrate the clinical advantages of its emu™ bedside brain scanner in regional and remote hospitals. The study targets facilities without ready CT access, where stroke diagnosis traditionally requires lengthy patient transfers. With site visits completed at two remote South Australian hospitals, protocol drafting well underway, and a $337,425 progress payment received under the Cooperative Research Centres Projects (CRC-P) program, EMVision is positioning the emu™ as a potential game-changer in rural stroke care.

Integrating emu™ into Telestroke Workflows

The study's workflow design is progressing in close collaboration with South Australia’s telestroke service, aiming to embed the emu™ scanner within existing stroke care pathways. This integration will allow scan results to be available to consulting neurologists during telehealth consultations, enhancing diagnostic speed and accuracy. The study’s approach represents a shift from merely identifying transfer candidates to enabling on-site diagnosis and treatment decisions, which could significantly reduce delays in critical stroke interventions.

Relevance Beyond Australia: US Rural Hospitals in Focus

The study's findings are expected to resonate with the US healthcare sector, particularly within the approximately 1,300 Critical Access Hospitals (CAHs) serving rural communities. Like the South Australian sites, these small hospitals often lack 24/7 CT imaging and advanced diagnostic tools necessary for timely stroke care. EMVision has previously identified around 330 CAHs in the US 'Stroke Belt' as priority targets for its emu™ launch. The evidence generated from the Regional Benefits Study will be crucial in supporting adoption in these settings, where stroke mortality rates remain disproportionately high.

Next Steps and Commercial Implications

Following protocol finalisation, EMVision will seek ethics approvals, site contracting, and research governance clearances, with potential expansion to additional study sites. The company’s CEO Scott Kirkland emphasised the study’s aim to address inequities in rural stroke outcomes by moving diagnosis closer to the patient. This initiative dovetails with EMVision’s broader clinical programs, including its pivotal emu™ trial which recently surpassed 200 patients enrolled and is progressing towards FDA milestones, underscoring the company’s momentum in both Australian and US markets emu™ trial recruitment exceeds 200 patients.

With Medicare’s cost-based reimbursement model for CAHs potentially easing capital equipment adoption, EMVision’s evidence-based approach could unlock significant commercial opportunities. The study’s focus on operationalising the emu™ in nurse-led emergency departments without on-site CT scanners also complements recent validations of the device’s aeromedical feasibility, supporting its use in diverse rural healthcare settings Successful aeromedical feasibility study completed.

Bottom Line?

EMVision’s Regional Benefits Study could redefine rural stroke diagnosis, but commercial impact hinges on successful integration and evidence generation in challenging healthcare environments.

Questions in the middle?

• Will the Regional Benefits Study confirm meaningful clinical benefits to accelerate emu™ adoption?
• How quickly can EMVision expand the study to additional sites and translate findings into US market strategies?
• What operational challenges might arise when integrating emu™ scans into existing telestroke workflows?